Tuberculosis in renal transplant recipients on various immunosuppressive regimens

Basit Öğe Kaydı
dc.contributor.authorAtasever, A
dc.contributor.authorBacakoglu, F
dc.contributor.authorToz, H
dc.contributor.authorBasoglu, OK
dc.contributor.authorDuman, S
dc.contributor.authorBasak, K
dc.contributor.authorGuzelant, A
dc.contributor.authorSayiner, A
dc.date.accessioned2019-10-27T18:58:35Z
dc.date.available2019-10-27T18:58:35Z
dc.date.issued2005
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground. Mycophenolate mofetil (MMF) and tacrolimus (TAC) are more potent than conventional immunosuppressive drugs, i.e. azathioprine, cyclosporin and prednisolone, and may be associated with an increase in the incidence of infections in the post-transplantation (post-tx) period. The aim of this study was to determine if the use of either or both of MMF and TAC for immunosuppression in renal transplant recipients increases the prevalence or modifies the clinical presentation of tuberculosis (TB), when compared with conventional therapy. Methods. The medical records of 443 adult patients who received a kidney transplant between 1994 and 2002 were reviewed retrospectively. Comparisons were made between patients who had conventional immunosuppressive treatments (cyclosporin, azathioprine and prednisolone) or an alternative regimen (including MMF, TAC or both). Results. We found 20 patients (4.5%) to have post-tx TB. There were 13 cases of TB (age 38.9 +/- 10.6 years) among 328 patients who received conventional immunosuppressants (group I) (4.0%) and seven cases (age 24.2 +/- 17.4 years) among 115 (6.1%) who received an alternative immunosuppressive regimen (group II) (P > 0.05). The patients in group II were younger than the patients in group I (P=0.002). A significantly higher number of patients in group II developed TB within the first 6 months post-tx (P=0.042). However, there was no significant difference between the two groups regarding clinical and radiographic presentations or outcomes. Conclusions. Immunosuppression with TAC or MMF is associated with the development of TB earlier in the post-tx period and in younger patients.en_US
dc.identifier.doi10.1093/ndt/gfh691en_US
dc.identifier.endpage802en_US
dc.identifier.issn0931-0509
dc.identifier.issn1460-2385
dc.identifier.issue4en_US
dc.identifier.pmid15703207en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage797en_US
dc.identifier.urihttps://doi.org/10.1093/ndt/gfh691
dc.identifier.urihttps://hdl.handle.net/11454/37503
dc.identifier.volume20en_US
dc.identifier.wosWOS:000228439500022en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofNephrology Dialysis Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectmycophenolate mofetilen_US
dc.subjectrenal transplantationen_US
dc.subjecttacrolimusen_US
dc.subjecttuberculosisen_US
dc.titleTuberculosis in renal transplant recipients on various immunosuppressive regimensen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu